'Ca19 9' presentation slideshows

Sviluppi futuri di nab -Paclitaxel nel carcinoma metastatico del pancreas

673 views • 34 slides

Background

Phase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : an Eastern Cooperative Oncology Group Study (E8200).

466 views • 32 slides

RADIOIMMUNOASSAY (RIA)

RADIOIMMUNOASSAY (RIA). INTRODUCTION. RIA is a nuclear technique widely used for measuring minute substances with IN VITRO Procedures.

2.36k views • 21 slides

Results of a Randomized Phase III Trial (MPACT) of Weekly nab -Paclitaxel Plus

Results of a Randomized Phase III Trial (MPACT) of Weekly nab -Paclitaxel Plus Gemcitabine vs Gemcitabine Alone for Patients With Metastatic Adenocarcinoma of the Pancreas With PET and CA19-9 Correlates.

445 views • 18 slides

1 UCSF Comprehensive Cancer Center, San Francisco, CA 2 Arlington Cancer Center, Arlington, TX

Phase 2, Randomized, Open-label Study of Cetuximab and Bevacizumab Alone or in Combination with Fixed-dose Rate (FDR) Gemcitabine as First-line Therapy of Patients with Metastatic Adenocarcinoma of the Pancreas (MPC).

253 views • 17 slides

Supplementary Figure 1. CA19-9 and sLe x expression correlated with FUT3 and FUT6

143 views • 5 slides

Figure 1

a. b. c. Figure 1. a. b. c. Figure 2. CK7. MUC1. Figure 3. MUC4. p63. MUC2. MUC6. CEA. CA19-9. PASD. MUC5AC.

189 views • 2 slides